Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
2 Different MYDX VIDEO'S: Saying stay tuned for MYDX Pen. 243 views so far.
PER 10k dated 04/25/19 - The Dewald/Sanzeri case "HAS NOT BEEN DISMISSED".
Lawsuit Against Jerome Dewald and Skip Sanzeri
As previously disclosed, in July 2017, the Company and its CEO (collectively, the “Plaintiffs”) filed a lawsuit against Jerome Dewald and Skip Sanzeri. On or about July 9, 2018, the Company settled with Mr. Dewald and has dismissed the matter with prejudice as to Mr. Dewald. On or about July 25, 2018, the Company settled with Mr. Sanzeri, which settlement calls for settlement payments of $1,000 per month over the course of five months, after which the Company will dismiss the matter as to Mr. Sanzeri and fully dispose of the lawsuit. As of April 23, 2019, all five $1,000 payments have been made to the Company and the matter has not yet been dismissed.
MYDX Eco Smart Pen and app picture: I guess this picture doesn't exist either. LMAO.
https://investorshub.advfn.com/uimage/uploads/2018/9/10/cssxwCOINS2.PNG
MYDX NO.4 on Most Posted Cannabis Stocks.
That is a definite possibility also..
Apparently forgot to mention the following, as of April 25, 2019 'The MyDx Analyzer with CannaDx Sensor (CannaDx) - These issues have now resolved and we expect to begin filling our back log of orders, which we could not recognize as sales in 2018, in the second quarter of 2019.
The Dewald/Sanzeri case "HAS NOT BEEN DISMISSED" per 10k dated 04/25/19.
Lawsuit Against Jerome Dewald and Skip Sanzeri
As previously disclosed, in July 2017, the Company and its CEO (collectively, the “Plaintiffs”) filed a lawsuit against Jerome Dewald and Skip Sanzeri. On or about July 9, 2018, the Company settled with Mr. Dewald and has dismissed the matter with prejudice as to Mr. Dewald. On or about July 25, 2018, the Company settled with Mr. Sanzeri, which settlement calls for settlement payments of $1,000 per month over the course of five months, after which the Company will dismiss the matter as to Mr. Sanzeri and fully dispose of the lawsuit. As of April 23, 2019, all five $1,000 payments have been made to the Company and the matter has not yet been dismissed.
Agree, I am also. MYDX has been and is very quiet with what they are doing. Anything is possible. They worked with University of Florida for a year before that news was released to the public.
MYDX could be hiding the announcement of a 'newco' with Ganga Gold and partnership with the ECO SMART PEN, the partnership with MR.Cannibas and ECO SMART PEN, the possible merger/acquisition with CRYOPORT, the shipping date of the ECO SMART PEN from MYDX, the announcement of other NEW partners with mydx, and I could keep going on. No rush for 10q per WALDO until MYDX is 100 percent ready. MYDX long shareholders don't care when it comes out .
Very good point.
Agree, it is now 4 days that MYDX could have filed a revised 8k if it was warranted. They have not done so thus far.
It's still up for debate, I can't imagine why MYDX would use as an example. MYDX has an accounting firm that does all their SEC filings that is different then Cryoport's. MYDX itself would not file an 8k by them selves.
MYDX Eco Smart Pen and app picture: I guess this picture doesn't exist either. LMAO.
https://investorshub.advfn.com/uimage/uploads/2018/9/10/cssxwCOINS2.PNG
MYDX RECRUITS MR. CANNABIS GROUP TO OPERATE COMPANY,
https://www.globenewswire.com/news-release/2018/11/13/1650316/0/en/MYDX-RECRUITS-MR-CANNABIS-GROUP-TO-OPERATE-COMPANY.html
MYDX at MEDMEN Headquarters. Quote 'MYDX it’s gonna be a great year'
https://www.instagram.com/p/BtMvBI8AbuB/
MYDX interview where Daniel says MYDX has a smart pen and mydx created a smart pen for Mr.Cannibas.
CFN Media Interviews MyDx Inc. (MYDX) at NCIA 2018 https://www.cannabisfn.com/cfnvideo/?id=lXSj78HA
Where's the 7 million ask at 15 that was there 30 minutes before the close yesterday, just another scare tactic. lol.
How's this picture http://sharc-research.org/2018/10/16/sharc-student-andrew-fiore-to-use-portable-marijuana-analyzer-in-pilot-study/ showing a STUDENT AT UNIVERSITY OF FLORIDA holding a CannaDx tester!!!!
How's this picture http://sharc-research.org/2018/10/16/sharc-student-andrew-fiore-to-use-portable-marijuana-analyzer-in-pilot-study/ showing a STUDENT AT UNIVERSITY OF FLORIDA holding a CannaDx tester with the quote of
'We are excited to share that student Andrew Fiore will be pursuing the use of the CannaDx sensor in a limited pilot study to evaluate the interest of marijuana analyzers in research participants!
This project highlights SHARC’s leading research that works to answer pressing questions about marijuana use. We are excited to see to follow Andrew’s progress.
SAN DIEGO, CA, Sept. 28, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE - MyDx, Inc. (OTC: MYDX), a leader in science based cannabis health technologies, is proud to announce that the University of Florida will be using our flagship product, the CannaDx Analyzer, in the largest prospective study to date focused on the health effects of marijuana in people living with HIV.
“With this study, we are taking an additional step in solidifying our position as a leader in science based cannabis health technologies. The CannaDx Analyzer is expected to be used in a large pre-clinical long term cannabis study that will track patient data,” stated Daniel Yazbeck, CEO of MyDx. “The science of cannabis is still in its infancy. Studies like these, conducted by reputable institutions like the University of Florida, and supported by MyDx, are paving the way for the future of cannabis science in this country.”
We first entered communications with the University of Florida back in December of 2017. After reviewing the CannaDx Analyzer’s specifications, abilities, and corresponding software application, we are happy to announce that our platform was the one selected for the study.
This is intended to be a long-term study to be conducted over the course of up to 5 years that has the potential to produce valuable data which could contribute to the future possibilities of cannabis being used as a real medicine.
Marijuana and Potential Long-term Effects Study Goals
The overarching goals of this study are to obtain evidence regarding the influence of marijuana on major health outcomes and behavior in persons living with HIV in order to help guide clinical recommendations and identify risk factors for consequences. The research team is especially interested in the relationship of marijuana to novel aspects of cognitive function (e.g. motivation, intention, planning) and to systemic inflammation.
The study will enroll 480 total participants, including 360 marijuana users and 120 non-users. Participants will be asked to complete a baseline visit, with yearly follow-up visits for up to five years.
During a visit, participants will be asked to:
Give a small blood sample
Give a small urine sample
Complete a 45-minute survey about their marijuana, alcohol, and drug use, sexual activity, pain levels, and mood
Complete approximately 2 hours of thinking and memory tasks on paper and on an iPad
The study would like to ask the participants to analyze the marijuana product that they consume using the MyDx device. This will be done by allowing participants to take the device home with a study phone that has the app on it to do a one-time test of their marijuana product. They will also enter some information in the app associated with their marijuana use (e.g., ailments trying to relieve, side effects).
The findings will inform HIV treatment providers and patients who are considering marijuana to manage HIV-related symptoms or the HIV disease itself, and will identify patterns of marijuana use that are most strongly associated with the incidence of substance use disorders.
The application of the MyDx analyzer in this study further solidifies our positioning of the company for a future exit.
2 Different Ganga Gold VIDEO'S: Saying stay tuned for MYDX Pen. 241 views so far.
I think it is your conclusion that is the mistake about MYDX.
If you look at Cryoport's past sec filings there are quite a few others that have signed as 'Principal Officer's', could be that Matt from MYDX is on cryoport's Board.
LMAO, Maybe some should pay attention to the MYDX 8k's that they speak so much about, and they would have seen that Matt signed the 8K as 'Principal Executive Officer' - NOT CEO! Great DD.
Sadler, Gibb and Associates are MYDX's accounting firm.
KMJ Corbin & Company is the accounting firm for CRYOPORT. So both MYDX and CRYOPORT use different accounting firms. Trying to rule out the possibility of a mistake on the last 2 MYDX 8K's. Looking promising for a merger/acquisition together.
So far I have confirmed that MYDX and Cryoport use different accounting firms for their SEC filings. To me, that fact would rule out the possibility that the same firm prepared both companies SEC paperwork's and just used Cryoport's 8k form as a template and forgot to remove Cryoport from the signature line.
Still NO revised MYDX 8K's, MYDX longs know what that means.
2 Different Ganga Gold VIDEO'S: Saying stay tuned for MYDX Pen. 241 views so far.
Waldo has seen the 10q, he says to not worry - BIG NEWS IS COMING(but don't let on that you know).
2 Different Ganga Gold VIDEO'S: Saying stay tuned for MYDX Pen. 238 views so far.
How's this picture http://sharc-research.org/2018/10/16/sharc-student-andrew-fiore-to-use-portable-marijuana-analyzer-in-pilot-study/ showing a STUDENT AT UNIVERSITY OF FLORIDA holding a CannaDx tester with the quote of
'We are excited to share that student Andrew Fiore will be pursuing the use of the CannaDx sensor in a limited pilot study to evaluate the interest of marijuana analyzers in research participants!
This project highlights SHARC’s leading research that works to answer pressing questions about marijuana use. We are excited to see to follow Andrew’s progress.
SAN DIEGO, CA, Sept. 28, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE - MyDx, Inc. (OTC: MYDX), a leader in science based cannabis health technologies, is proud to announce that the University of Florida will be using our flagship product, the CannaDx Analyzer, in the largest prospective study to date focused on the health effects of marijuana in people living with HIV.
“With this study, we are taking an additional step in solidifying our position as a leader in science based cannabis health technologies. The CannaDx Analyzer is expected to be used in a large pre-clinical long term cannabis study that will track patient data,” stated Daniel Yazbeck, CEO of MyDx. “The science of cannabis is still in its infancy. Studies like these, conducted by reputable institutions like the University of Florida, and supported by MyDx, are paving the way for the future of cannabis science in this country.”
We first entered communications with the University of Florida back in December of 2017. After reviewing the CannaDx Analyzer’s specifications, abilities, and corresponding software application, we are happy to announce that our platform was the one selected for the study.
This is intended to be a long-term study to be conducted over the course of up to 5 years that has the potential to produce valuable data which could contribute to the future possibilities of cannabis being used as a real medicine.
Marijuana and Potential Long-term Effects Study Goals
The overarching goals of this study are to obtain evidence regarding the influence of marijuana on major health outcomes and behavior in persons living with HIV in order to help guide clinical recommendations and identify risk factors for consequences. The research team is especially interested in the relationship of marijuana to novel aspects of cognitive function (e.g. motivation, intention, planning) and to systemic inflammation.
The study will enroll 480 total participants, including 360 marijuana users and 120 non-users. Participants will be asked to complete a baseline visit, with yearly follow-up visits for up to five years.
During a visit, participants will be asked to:
Give a small blood sample
Give a small urine sample
Complete a 45-minute survey about their marijuana, alcohol, and drug use, sexual activity, pain levels, and mood
Complete approximately 2 hours of thinking and memory tasks on paper and on an iPad
The study would like to ask the participants to analyze the marijuana product that they consume using the MyDx device. This will be done by allowing participants to take the device home with a study phone that has the app on it to do a one-time test of their marijuana product. They will also enter some information in the app associated with their marijuana use (e.g., ailments trying to relieve, side effects).
The findings will inform HIV treatment providers and patients who are considering marijuana to manage HIV-related symptoms or the HIV disease itself, and will identify patterns of marijuana use that are most strongly associated with the incidence of substance use disorders.
The application of the MyDx analyzer in this study further solidifies our positioning of the company for a future exit.
2 Different Ganga Gold VIDEO'S: Saying stay tuned for MYDX Pen. 235 views so far.
MyDx EcoSmartPen
We have begun conversations with multiple nationwide Cannabis brands who are interested in partnering with MyDx and the EcoSmartPenTM to deploy within their existing sales channels. We look forward to completing these contracts and announcing the first of these once our pen has been completed and manufactured at a scale and is ready for deployment with our partners’ approval.
2 Different Ganga Gold VIDEO'S: Saying stay tuned for MYDX Pen. 234 views so far.
MYDX and CRYOPORT both use DIFFERENT accounting firms, that rules out possible mistake of using same form. NO REVISION on 8K after 3 business days so far. BIG NEWS COMING.
PER 10k dated 04/25/19 The Dewald/Sanzeri case "HAS NOT BEEN DISMISSED"
Lawsuit Against Jerome Dewald and Skip Sanzeri
As previously disclosed, in July 2017, the Company and its CEO (collectively, the “Plaintiffs”) filed a lawsuit against Jerome Dewald and Skip Sanzeri. On or about July 9, 2018, the Company settled with Mr. Dewald and has dismissed the matter with prejudice as to Mr. Dewald. On or about July 25, 2018, the Company settled with Mr. Sanzeri, which settlement calls for settlement payments of $1,000 per month over the course of five months, after which the Company will dismiss the matter as to Mr. Sanzeri and fully dispose of the lawsuit. As of April 23, 2019, all five $1,000 payments have been made to the Company and the matter has not yet been dismissed
LMAO, Maybe we should call ganga gold also, lol
All the way at bottom is signature.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 7, 2019
MYDX, INC.
(Exact name of registrant as specified in its charter)
Nevada
000-55596
99-0384160
(State of other jurisdiction
of incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
6335 Ferris Square, Suite B, San Diego, CA 92121
(Address of principal executive offices, including zip code)
Registrant’s telephone number, including area code: (800) 814-4550
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
?
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
?
Soliciting material pursuant to Rule 14A-12 under the Exchange Act (17 CFR 240.14a-12)
?
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR.14d-2(b))
?
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
None
None
None
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ?
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ?
Item 1.01.
Entry into a Material Definitive Agreement.
On May 7, 2019, MyDx, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with Odyssey Capital Funding, LLC (“Odyssey”) for the sale of an 12% convertible redeemable note in the amount of $100,000 (the “Note”).
The Note bears interest at the rate of 12% per annum. All interest and principal must be repaid on May 7, 2020 (the “Maturity Date”). The Note is convertible into common stock at any time after the six month anniversary of this Note, at Odyssey’s option, at a price equal to 60% of the lowest closing trading price of the common stock during the twenty day period prior to conversion (the “Conversion Price”). The Note may not be prepaid more than 180 days prior to the Maturity Date. In the event the Company prepays the Note in full during the 180 days prior to the Maturity Date, the Company must pay off all principal, interest and any other amounts owing multiplied by a premium ranging from 25% to 45%.
Odyssey has agreed to restrict its ability to convert the Note and receive shares of common stock such that the number of shares of common stock held by them in the aggregate and their affiliates after such conversion or exercise does not exceed 4.99% of the then issued and outstanding shares of common stock. The Note is a debt obligation arising other than in the ordinary course of business which constitute a direct financial obligation of the Company.
This Note contains default events (an “Event of Default”) which, if triggered and not timely cured (if curable) by the Company, will result in the option by Odyssey to consider the Note immediately due and payable, without presentment, demand, protest or (further) notice of any kind (other than notice of acceleration). Upon an Event of Default, interest shall accrue at a default interest rate of 24% per annum or, if such rate is usurious or not permitted by current law, then at the highest rate of interest permitted by law.
The Note was offered and sold to Odyssey in a private placement transaction made in reliance upon exemptions from registration pursuant to Section 4(a)(2) under the Securities Act of 1933 (the “Securities Act”) and/or Rule 506 promulgated under the Securities Act. Odyssey is an accredited investor as defined in Rule 501 of Regulation D promulgated under the Securities Act.
The foregoing summary of the terms of the Securities Purchase Agreement and the Note is qualified in its entirety by the Securities Purchase Agreement, which is attached as Exhibits 4.1 and 10.1 to this Current Report on Form 8-K and incorporated herein by reference.
Item 2.03
Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of a Registrant.
The disclosure set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.
Item 3.02
Unregistered Sales of Equity Securities.
The disclosure set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.
Item 9.01.
Financial Statements and Exhibits
(d)
Exhibits.
The following material is filed as an exhibit to this Report:
Exhibit
Number
4.1
12% Convertible Redeemable Note issued to Odyssey Capital Funding, LLC dated May 7, 2019.
10.1
Securities Purchase Agreement, dated as of May 7, 2019, by and between Odyssey Capital Funding, LLC and MyDx, Inc.
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CRYOPORT, INC.
Date: May 24, 2019
By:
/s/ Matthew Bucciero
Matthew Bucciero
Principal Executive Officer
2
2 Different Ganga Gold VIDEO'S: Saying stay tuned for MYDX Pen. 231 views so far.
Sadler, Gibb and Associates are MYDX's accounting firm.
KMJ Corbin & Company is the accounting firm for CRYOPORT. So both MYDX and CRYOPORT use different accounting firms. Trying to rule out the possibility of a mistake on the last 2 MYDX 8K's. Looking promising for a merger/acquisition together.